firstscript

Clinical Bulletin

December 30, 2019

Subject: UBRELVY™ Approval on December 23, 2019

The U.S. Food and Drug Administration (FDA) has recently approved UBRELVY (ubrogepant) for the treatment of migraine attacks, with or without aura, in adults. It works in a novel way by blocking calcitonin gene-related peptide (CGRP), a protein that is released during migraines, from binding to their receptors. Unlike many of the current treatments, it works without constricting blood vessels and is currently the first and only oral CGRP receptor antagonist that is FDA-approved.

In clinical trials, UBRELVY gained FDA approval due to meeting goals of pain relief and elimination of migraines' most troublesome features (nausea and hypersensitivity to sight or sounds). UBRELVY was approved as both 50 and 100 mg oral dose for treatment of migraine attacks, but not prevention, due to efficacy after two hours of onset versus placebo. UBRELVY demonstrated low rate of side effects during the clinical trials compared to placebo, the most common of which were nausea, tiredness, and dry mouth.

Migraines are a very common disease in America that can lead to disabling effects for injured workers. UBRELVY joins the newer CGRP inhibitors (Aimovig®, AJOVY®, Emgality®) as a potent new agent for migraine treatment whereas the other newer agents are used for prevention and only available as injectable pre-filled syringes.

The Impact

Migraine treatments represent a small number of active prescriptions for First Script injured workers. First Script will continue monitoring the use of UBRELVY and any impact it may have. For more information, please contact your Account Manager or Account Pharmacist.

For additional information about UBRELVY visit: UBRELVY.com